NXC-201 Delivers Breakthrough Results In Relapsed/Refractory AL Amyloidosis; Market Potential Drives IMMX Higher

Immix Biopharma Inc. (IMMX) stock jumped to $6.65 in pre-market trading—a nearly 20% surge—following encouraging Phase 2 data from the NEXICART-2 trial unveiled at the American Society of Hematology 2025 Annual Meeting.

The Clinical Challenge and Disease Context

Relapsed/refractory AL Amyloidosis represents one of medicine’s toughest obstacles. This rare but devastating condition stems from abnormal plasma cells in the bone marrow that produce misfolded amyloid proteins. These protein deposits progressively accumulate in critical organs—the heart, kidneys, and liver—triggering cascading multi-organ failure and carrying high mortality rates. Current treatment options remain limited, with existing therapies achieving complete response rates of 10% or below, leaving a significant clinical gap.

NEXICART-2 Trial Design and Phase 2 Outcomes

The NEXICART-2 initiative is a single-arm, multi-site Phase I/II U.S. study evaluating NXC-201 in patients with relapsed/refractory AL Amyloidosis. While Phase I prioritized safety assessment, the Phase II portion focused on efficacy metrics. The Phase 2 results revealed compelling efficacy: NXC-201 achieved a 75% complete response (CR) rate as confirmed by independent review committee assessment.

Beyond the headline 75% figure, the data suggests even greater potential. Among five pending patients, four demonstrated MRD negativity in bone marrow—meaning no measurable residual disease. This biomarker pattern historically predicts subsequent complete response achievement, potentially lifting the CR rate to 95% upon final data maturation.

Commercial and Regulatory Pathway

The significant gap between standard-of-care response rates (10% or below) and NXC-201’s demonstrated efficacy (75% current, up to 95% projected) positions this candidate as a potential first-in-class approved therapy for this indication. Immix plans to submit a Biologics License Application (BLA) in 2026 following the anticipated final data readout from NEXICART-2.

Gabriel Morris, Chief Financial Officer of Immix Biopharma, stated: “This Phase 2 milestone represents a meaningful step toward bringing this promising therapy to patients through our planned 2026 BLA submission.”

Market Response and Investor Perspective

IMMX shares have gained momentum since September 2025, when the stock traded near $2.20, climbing to $5.56 by Friday, December 5—a 152% increase over roughly three months. Yesterday’s Phase 2 announcement contributed to further appreciation, reflecting investor confidence in the candidate’s therapeutic potential and regulatory timeline.